Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

1. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.BMJ (Clinical research ed.) · 2022
   Pooled it
2. Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.PLoS medicine · 2022
   Trial
3. Venous and arterial thromboembolic events after COVID-19 during the Omicron period in three European countries.Scientific reports · 2026
   Article
4. Epidemiology of Thrombotic Thrombocytopenia Syndrome 2011 to 2022: English Sentinel Network Cohort Studies.Drug safety · 2025
   Article
5. Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination.Drug safety · 2024
   Article
6. The incidence of thrombosis with co-occurring thrombocytopenia prior to the SARS-CoV2 pandemic: A population-based study.PloS one · 2024
   Observational
7. Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network Study.Drug safety · 2023
   Article
8. Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.Vaccine · 2023
   Article
9. COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics).Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2023
   Review
10. Venous or arterial thrombosis in COVID-19 cases in the North Carolina COVID-19 Community Research Partnership (NC-CCRP).Research and practice in thrombosis and haemostasis · 2023
    Article
11. Background rate estimations for thrombosis with thrombocytopaenia: challenges in evaluating rare safety signals following vaccination in real time during a pandemic.BMJ open · 2023
    Article
12. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.Vaccine · 2023
    Article
13. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study.Vaccine · 2023
    Article
14. Incidence of sinus thrombosis with thrombocytopenia-A nation-wide register study.PloS one · 2023
    Article
15. Transforming the Information System for Research in Primary Care (SIDIAP) in Catalonia to the OMOP Common Data Model and Its Use for COVID-19 Research.Clinical epidemiology · 2023
    Article
16. Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study).BMJ medicine · 2023
    Article
17. Transforming and evaluating the UK Biobank to the OMOP Common Data Model for COVID-19 research and beyond.Journal of the American Medical Informatics Association : JAMIA · 2022
    Observational
18. Data standards and standardization: The shortest plank of bucket for the COVID-19 containment.The Lancet regional health. Western Pacific · 2022
    Review
19. Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study.The Lancet. Infectious diseases · 2022
    Article
20. Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study.Drug safety · 2022
    Observational

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

18 authors at 8 institutions in 4 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as